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Sir,
The British Society of Echocardiography, whose 2400 members
represent physiologists (technicians) and clinicians performing
echocardiography in the UK, has welcomed the recent NICE
guidelines on the use of Trastuzumab.
We are aware of the importance of monitoring left ventricular
(LV) function and believe echocardiography and BSE accredited
echocardiogrpahers are ideally placed to perform this monitoring.
We have issued a statement (also available at www.bsecho.org
under ‘Guidelines’) to our members, which, we also believe will be
of importance and interest to Oncologists.
British Society of Echocardiography – Statement to Members
The evaluation of left ventricular function for patients being
considered or receiving Trastuzumab (Herceptin) therapy
1. The NICE have recently extended their guidance on indications
for Trastuzumab. As part of the care of patients considered for
Trastuzumab pre-treatment measurement of LV function is
required and 3 monthly during treatment according to most
protocols. This is because of the known potential for cardiac
damage occurring in patients receiving Trastuzumab.
2. Although local guidelines may vary, current guidelines typically
state that patients should not normally be commenced on
Trastuzumab if their baseline Ejection Fraction (EF) is p55%.
If the EF falls by more than 10% or to o50% cessation of
treatment should be considered.
3. Echocardiography is an ideal technique for the evaluation of LV
function. A small number of patients, usually owing to local
surgery, may have unacceptably poor images and should be
considered for an alternative imaging modality.
4. Ejection Fraction can be disputed as the optimal method of
describing LV function but it has been chosen in considerations
regarding Trastuzumab therapy.
5. The exacting nature of the guidelines require accurate
measurement of EF. This is likely to be only possible by the
use of (biplane) Simpson’s Rule Method or 3D echocardio-
graphy, with the availability of contrast for LV opacification, by
appropriately skilled echocardiographers.
6. Echo laboratories performing such studies should have
evidence (e.g. through audit or other Quality Control pro-
cesses), not more than 12 months old, that they can
reproducibly measure EF to the requirements of the guidelines.
This means that they can identify a 10% change in EF as a true
change.
7. Cardiology departments and oncology departments should
cooperate closely in individual (borderline) cases and in the
provision of the echo service.
8. It is unreasonable to expect already hard pressed echo
laboratories to absorb a significant increase in workload
relating to Trastuzumab therapy without consideration of the
provision of appropriate resources (staff, machine time, and
funds). This should be resolved locally.
The Council of the British Society of Echocardiography, June
2006.
Published online 24 October 2006
*Correspondence: KF Fox; E-mail: admin@bsecho.org
British Journal of Cancer (2006) 95, 1454
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com